Ellen Kullman - Amgen Insider

Amgen Inc -- USA Stock  

USD 183.55  0.05  0.0272%


Ms. Ellen J. Kullman serves as Director of the Company. Ms. Kullman has served as a director of the Company since October 14, 2016. Ms. Kullman was first identified to the Governance and Nominating Committee as a potential director candidate by the Companys outside search firm. Ms. Kullman is the former President, Chair and Chief Executive Officer of E.I. du Pont de Nemours and Company, or DuPont, a science and technologybased company, where she served from January 2009 to October 2015. Prior to this, Ms. Kullman served as President of DuPont from October 2008 to January 2009. From June 2006 through September 2008, she served as Executive Vice President of DuPont. Prior to that, Ms. Kullman was Group Vice President, DuPont Safety and Protection. Ms. Kullman was a director of United Technologies Corporationrationration, a technology products and services company, since 2011, serving on its Committee on Compensation and Executive Development and Chairing its Committee on Governance and Public Policy. Ms. Kullman was a director of Goldman Sachs Group, Inc., an investment banking firm, since December 2016, serving on its Compensation, Corporationrationrate Governance and Nominating, and Risk Committees. Ms. Kullman served as a director of General Motors, from 2004 to 2008, serving on its Audit Committee. Ms. Kullman joined the board of directors of Dell Technologies, a privatelyheld technology company, and the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore
Age: 60  Director Since 2016      
805-447-1000  http://www.amgen.com
Kullman received a bachelor of science in mechanical engineering degree from Tufts University and a master?s degree from the Kellogg School of Management at Northwestern University.

Ellen Kullman Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.32 % which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 7.18 % meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


David AltshulerVertex Pharmaceuticals Incorpor
Ron TaylorAllergan plc
Yuchun LeeVertex Pharmaceuticals Incorpor
David GreenwayVertex Pharmaceuticals Incorpor
Christopher BodineAllergan plc
Sharad MansukaniEndo International plc
William OsbornAbbott Laboratories
William YoungVertex Pharmaceuticals Incorpor
Daniel StarksAbbott Laboratories
Nesli BasgozAllergan plc
Margaret McGlynnVertex Pharmaceuticals Incorpor
Edward LiddyAbbott Laboratories
Peter McDonnellAllergan plc
Arthur HigginsEndo International plc
Deborah NeffBio Rad Laboratories Inc
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
John StrattonAbbott Laboratories
Samuel ScottAbbott Laboratories
Fred WeissAllergan plc
Louis DrapeauBio Rad Laboratories Inc
William SpenglerEndo International plc

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Cryptocurrency Center Now

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Hide  View All  NextLaunch Cryptocurrency Center
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators